Clinical trials investigating histone deacetylase inhibitors (HDACi) to reverse HIV-1 latency
aim to expose reservoirs in antiretroviral (ARV)-treated individuals to clearance by immune …

HIV remains incurable due to the persistence of a latent viral reservoir found in HIV-infected
cells, primarily resting memory CD4+ T cells. Depletion of this reservoir may be the only way …

Combinations of drugs that affect distinct mechanisms of HIV latency aim to induce robust
latency reversal leading to cytopathicity and elimination of the persistent HIV reservoir. Thus …

Histone deacetylase (HDAC) inhibitors (HDACis) have been widely tested in clinical trials for
their ability to reverse HIV latency but have yielded only limited success. One HDACi …

Latent HIV persists in CD4+ T cells in infected patients under antiretroviral therapy (ART).
Latency is associated with transcriptional silencing of the integrated provirus and driven, at …

The existence of long-lived HIV-1-infected resting memory CD4 T cells is thought to be the
primary obstacle to HIV-1 eradication. In the search for novel therapeutic approaches that …

Antiretroviral therapy (ART) can control human immunodeficiency virus-1 (HIV-1) replication
in infected individuals. Unfortunately, patients remain persistently infected owing to the …

A long-lived latent reservoir of HIV-1-infected CD4 T cells persists with antiretroviral therapy
and prevents cure. We report that the emergence of latently infected primary CD4 T cells …

Persistence of HIV-1 in latently infected CD4+ T-cells prevents eradication in HIV-infected
treated patients. Latency is characterized by a reversible silencing of transcription of …

Histone deacetylase inhibitors (HDACi) are the most widely studied HIV latency-reversing
agents (LRAs). The HDACi suberoylanilide hydroxamic acid (vorinostat [VOR]) has been …